Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA ...

Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...

Analysts believe each of the stocks below has the potential to at least double in price, although the three firms also carry varying levels of risk.

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Hims & Hers Health (NYSE:HIMS) recently saw a significant stock price increase, jumping 140% over the past month. This rise ...

Prothena Corporation plc today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based ...

Contrarian investing advice from biotech and pharmaceutical stock expert Hartaj Singh, Founding Partner of Tecumseh Partners ...

Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the sovereign credit rating ...

The World Economic Forum recently spotlighted five healthcare breakthroughs, and at the top of the list was artificial intelligence. From surgical precision tools to real-time diagnostics, ...

U.S. companies are increasingly issuing bonds in the euro credit market as it is cheaper than issuing in the dollar credit market, CreditSights said. "A mix of European Central Bank policy loosening ...

Article originally published by. FE fundinfo is not responsible for its content or accuracy and may not share the author’s views. News and research are not personal recommendations to deal. All ...